BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Torres A, Chalmers JD, Dela Cruz CS, Dominedò C, Kollef M, Martin-Loeches I, Niederman M, Wunderink RG. Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med 2019;45:159-71. [PMID: 30706119 DOI: 10.1007/s00134-019-05519-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Huang D, He D, Gong L, Yao R, Wang W, Yang L, Zhang Z, He Q, Wu Z, Shi Y, Liang Z. A prediction model for hospital mortality in patients with severe community-acquired pneumonia and chronic obstructive pulmonary disease. Respir Res 2022;23. [DOI: 10.1186/s12931-022-02181-9] [Reference Citation Analysis]
2 Fan S, Si M, Xu N, Yan M, Pang M, Liu G, Gong J, Wang H. Metagenomic next-generation sequencing-guided antimicrobial treatment versus conventional antimicrobial treatment in early severe community-acquired pneumonia among immunocompromised patients (MATESHIP): A study protocol. Front Microbiol 2022;13:927842. [DOI: 10.3389/fmicb.2022.927842] [Reference Citation Analysis]
3 Wang M, Deng Z, Li Y, Xu K, Ma Y, Yang S, Wang J. Antibiofilm property and multiple action of peptide PEW300 against Pseudomonas aeruginosa. Front Microbiol 2022;13:963292. [DOI: 10.3389/fmicb.2022.963292] [Reference Citation Analysis]
4 Wang J, Hu H, Du H, Luo M, Cao Y, Xu J, Chen T, Guo Y, Li Q, Chen W, Zhang Y, Han J, Wan H. Clinical Efficacy Protocol of Yinhuapinggan Granules: A Randomized, Double-Blind, Parallel, and Controlled Clinical Trial Program for the Intervention of Community-Acquired Drug-Resistant Bacterial Pneumonia as a Complementary Therapy. Front Pharmacol 2022;13:852604. [DOI: 10.3389/fphar.2022.852604] [Reference Citation Analysis]
5 Milas S, Poncelet A, Buttafuoco F, Pardo A, Lali SE, Cherifi S. Antibiotic use in patients with Coronavirus disease 2019 (COVID-19): outcomes and associated factors. Acta Clin Belg 2022;77:579-87. [PMID: 33896399 DOI: 10.1080/17843286.2021.1916300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Van Besien RF, Hampton N, Micek ST, Kollef MH. Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia. Medicine (Baltimore) 2022;101:e29159. [PMID: 35608417 DOI: 10.1097/MD.0000000000029159] [Reference Citation Analysis]
7 Figuerêdo Moreira I, Marcelino Alvares-saraiva A, Cristin Pérez E, Guilherme Xavier J, Denelle Spadacci-morena D, Silva de Araújo R, Ricardo Dell'armelina Rocha P, Anete Lallo M. Opportunistic pneumonia caused by E. cuniculi in mice immunosuppressed with cyclophosphamide. Immunobiology 2022. [DOI: 10.1016/j.imbio.2022.152194] [Reference Citation Analysis]
8 Wu L, Ji J, Shi Y, Pallikonda Rajasekaran M. Value Comparison of Iterative Reconstruction Algorithm-Based Chest CT and Ultrasound in the Diagnosis of Community-Acquired Pneumonia in Children. Scientific Programming 2022;2022:1-8. [DOI: 10.1155/2022/9555847] [Reference Citation Analysis]
9 Kunz Coyne AJ, El Ghali A, Holger D, Rebold N, Rybak MJ. Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa. Infect Dis Ther 2022. [PMID: 35150435 DOI: 10.1007/s40121-022-00591-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
10 Yang L, He D, Huang D, Zhang Z, Liang Z. Development and Validation of Nomogram for Hospital Mortality in Immunocompromised Patients with Severe Pneumonia in Intensive Care Units: A Single-Center, Retrospective Cohort Study. IJGM 2022;Volume 15:451-63. [DOI: 10.2147/ijgm.s344544] [Reference Citation Analysis]
11 Hua J, Huang P, Liao H, Lai X, Zheng X. Prevalence and Clinical Significance of Occult Pulmonary Infection in Elderly Patients with Type 2 Diabetes Mellitus. Biomed Res Int 2021;2021:3187388. [PMID: 34901268 DOI: 10.1155/2021/3187388] [Reference Citation Analysis]
12 Li C, Ni YQ, Xu H, Xiang QY, Zhao Y, Zhan JK, He JY, Li S, Liu YS. Roles and mechanisms of exosomal non-coding RNAs in human health and diseases. Signal Transduct Target Ther 2021;6:383. [PMID: 34753929 DOI: 10.1038/s41392-021-00779-x] [Reference Citation Analysis]
13 Harris LK, Crannage AJ. Corticosteroids in Community-Acquired Pneumonia: A Review of Current Literature. J Pharm Technol 2021;37:152-60. [PMID: 34752553 DOI: 10.1177/8755122521995587] [Reference Citation Analysis]
14 Zhan Y, Xu T, He F, Guan WJ, Li Z, Li S, Xie M, Li X, Chen R, Cheng L, Zhong N, Ye F. Clinical Evaluation of a Metagenomics-Based Assay for Pneumonia Management. Front Microbiol 2021;12:751073. [PMID: 34603275 DOI: 10.3389/fmicb.2021.751073] [Reference Citation Analysis]
15 Pereverzeva L, Uhel F, Peters Sengers H, Cremer OL, Schultz MJ, Bonten MMJ, Scicluna BP, van der Poll T; MARS consortium. Association between delay in intensive care unit admission and the host response in patients with community-acquired pneumonia. Ann Intensive Care 2021;11:142. [PMID: 34585271 DOI: 10.1186/s13613-021-00930-5] [Reference Citation Analysis]
16 Li Q, Wu T, Li S. MiR-181b serves as diagnosis and prognosis biomarker in severe community-acquired pneumonia. Genet Mol Biol 2021;44:e20200431. [PMID: 34460893 DOI: 10.1590/1678-4685-GMB-2020-0431] [Reference Citation Analysis]
17 Wang Y. Effects of Doxofylline Combined with Ceftazidime on Clinical Efficacy, Drug Safety, and Prognosis in Patients with Chronic Obstructive Pulmonary Disease Complicated with Infection. Med Sci Monit 2021;27:e930494. [PMID: 34404757 DOI: 10.12659/MSM.930494] [Reference Citation Analysis]
18 Cutuli SL, Grieco DL, Menga LS, De Pascale G, Antonelli M. Noninvasive ventilation and high-flow oxygen therapy for severe community-acquired pneumonia. Curr Opin Infect Dis 2021;34:142-50. [PMID: 33470666 DOI: 10.1097/QCO.0000000000000715] [Reference Citation Analysis]
19 Du S, Wu X, Li B, Wang Y, Shang L, Huang X, Xia Y, Yu D, Lu N, Liu Z, Wang C, Liu X, Xiong Z, Zou X, Lu B, Liu Y, Zhan Q, Cao B. Clinical factors associated with composition of lung microbiota and important taxa predicting clinical prognosis in patients with severe community-acquired pneumonia. Front Med 2021. [PMID: 34302613 DOI: 10.1007/s11684-021-0856-3] [Reference Citation Analysis]
20 Lizza BD, Betthauser KD, Ritchie DJ, Micek ST, Kollef MH. New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam. Antimicrob Agents Chemother 2021;65:e0231820. [PMID: 33875428 DOI: 10.1128/AAC.02318-20] [Reference Citation Analysis]
21 Xie F, Duan Z, Zeng W, Xie S, Xie M, Fu H, Ye Q, Xu T, Xie L. Clinical metagenomics assessments improve diagnosis and outcomes in community-acquired pneumonia. BMC Infect Dis 2021;21:352. [PMID: 33858378 DOI: 10.1186/s12879-021-06039-1] [Reference Citation Analysis]
22 Rachina S, Zakharenkov I, Dekhnich N, Kozlov R, Sinopalnikov A, Ivanchik N, Sukhorukova M, Yatsyshina S, Arkhipenko M, Gordeeva S, Lebedeva M, Portnyagina U. Aetiology of severe community-acquired pneumonia and antimicrobial susceptibility of Streptococcus pneumoniae in adults in Russia. J Antimicrob Chemother 2021;76:1368-70. [PMID: 33604613 DOI: 10.1093/jac/dkab014] [Reference Citation Analysis]
23 Chen L, Han X, Li Y, Zhang C, Xing X. The Clinical Characteristics and Outcomes of Adult Patients With Pneumonia Related to Three Paramyxoviruses. Front Med (Lausanne) 2020;7:574128. [PMID: 33537323 DOI: 10.3389/fmed.2020.574128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
24 Liang J, Sun C, Xu L, Xu G, Cao H, Lin J. Community-Acquired Pneumonia and Hospital-Acquired Pneumonia in Adult Patients with Idiopathic Inflammatory Myopathy: Outcome and Antibiotic Therapy. Rheumatol Ther 2021;8:255-72. [PMID: 33369709 DOI: 10.1007/s40744-020-00268-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Sangla F, Legouis D, Marti PE, Sgardello SD, Brebion A, Saint-Sardos P, Adda M, Lautrette A, Pereira B, Souweine B. One year after ICU admission for severe community-acquired pneumonia of bacterial, viral or unidentified etiology. What are the outcomes? PLoS One 2020;15:e0243762. [PMID: 33315946 DOI: 10.1371/journal.pone.0243762] [Reference Citation Analysis]
26 Wu X, Li Y, Zhang M, Li M, Zhang R, Lu X, Gao W, Li Q, Xia Y, Pan P, Li Q. Etiology of Severe Community-Acquired Pneumonia in Adults Based on Metagenomic Next-Generation Sequencing: A Prospective Multicenter Study. Infect Dis Ther 2020;9:1003-15. [PMID: 33170499 DOI: 10.1007/s40121-020-00353-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
27 Rodríguez-Fanjul J, Guitart C, Bobillo-Perez S, Balaguer M, Jordan I. Procalcitonin and lung ultrasound algorithm to diagnose severe pneumonia in critical paediatric patients (PROLUSP study). A randomised clinical trial. Respir Res 2020;21:255. [PMID: 33032612 DOI: 10.1186/s12931-020-01476-z] [Reference Citation Analysis]
28 Vounotrypidis P. COVID-19: An Archetype Innate Immunity Reaction and Modes of Treatment. Mediterr J Rheumatol 2020;31:275-83. [PMID: 33196005 DOI: 10.31138/mjr.31.3.275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Arulkumaran N, Snow TAC, Longobardo A, Brealey D, Singer M. Steroids in ARDS: more light is being shed. Intensive Care Med 2020;46:2108-10. [PMID: 32886206 DOI: 10.1007/s00134-020-06230-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
30 Nair GB, Niederman MS. Updates on community acquired pneumonia management in the ICU. Pharmacol Ther 2021;217:107663. [PMID: 32805298 DOI: 10.1016/j.pharmthera.2020.107663] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
31 Crisafulli E, Manco A, Ferrer M, Huerta A, Micheletto C, Girelli D, Clini E, Torres A. Pneumonic versus Nonpneumonic Exacerbations of Chronic Obstructive Pulmonary Disease. Semin Respir Crit Care Med 2020;41:817-29. [PMID: 32726837 DOI: 10.1055/s-0040-1702196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Zhao B, Yu X, Chen R, Zheng R. Efficacy and Safety of Nemonoxacin in Outpatients with Community-Acquired Pneumonia. Infect Drug Resist 2020;13:2099-104. [PMID: 32669862 DOI: 10.2147/IDR.S248092] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Micek ST, Simmons J, Hampton N, Kollef MH. Characteristics and outcomes among a hospitalized patient cohort with Streptococcus pneumoniae infection. Medicine (Baltimore) 2020;99:e20145. [PMID: 32358404 DOI: 10.1097/MD.0000000000020145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Bassetti M, Russo A, Carnelutti A, Wilcox M. Emerging drugs for treating methicillin-resistant Staphylococcus aureus. Expert Opin Emerg Drugs 2019;24:191-204. [PMID: 31590576 DOI: 10.1080/14728214.2019.1677607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
35 Zhou B, Lou B, Liu J, She J. Serum metabolite profiles as potential biochemical markers in young adults with community-acquired pneumonia cured by moxifloxacin therapy. Sci Rep 2020;10:4436. [PMID: 32157124 DOI: 10.1038/s41598-020-61290-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Azeredo da Silveira S, Shorr AF. Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections-A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug. Antibiotics (Basel) 2020;9:E94. [PMID: 32098274 DOI: 10.3390/antibiotics9020094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
37 Bassetti M, Russo A, Cilloniz C, Giacobbe DR, Vena A, Amaro R, Graziano E, Soriano A, Torres A. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. Int J Antimicrob Agents 2020;55:105921. [PMID: 32061999 DOI: 10.1016/j.ijantimicag.2020.105921] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Wang J, Song YL. Advances in severe community-acquired pneumonia. Chin Med J (Engl) 2019;132:1891-3. [PMID: 31335475 DOI: 10.1097/CM9.0000000000000366] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Torres A, Loeches IM, Sligl W, Lee N. Severe flu management: a point of view. Intensive Care Med 2020;46:153-62. [PMID: 31912206 DOI: 10.1007/s00134-019-05868-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
40 Tanzella G, Motos A, Battaglini D, Meli A, Torres A. Optimal approaches to preventing severe community-acquired pneumonia. Expert Rev Respir Med 2019;13:1005-18. [PMID: 31414915 DOI: 10.1080/17476348.2019.1656531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Lan SH, Chang SP, Lai CC, Lu LC, Chao CM. Efficacy and Safety of Ceftaroline for the Treatment of Community-Acquired Pneumonia: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med 2019;8:E824. [PMID: 31181859 DOI: 10.3390/jcm8060824] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]